Global Finance News
01 Jan 2026, 15:36
Axsome Therapeutics Shares Surge After FDA Priority Review Boosts Outlook
Shares of Axsome Therapeutics rallied sharply this week following a major regulatory catalyst, drawing renewed investor attention to the company’s central nervous system pipeline. Axsome stock jumped more than 20% and traded in the low-$180s, marking one of its strongest weekly performances in recent years.
The rally was driven primarily by news that the U.S. Food and Drug Administration granted Priority Review to Axsome’s supplemental New Drug Application for AXS-05 in the treatment of agitation associated with Alzheimer’s disease. As reported by GlobeNewswire, the FDA set a target action date of April 30, 2026, significantly accelerating the regulatory timeline and increasing confidence in a potential label expansion for the company’s lead product.
Market reaction to the FDA decision was swift. Investing*com noted that the Priority Review designation pushed Axsome shares to record levels, reflecting investor optimism around the commercial potential of AXS-05 in a large and underserved patient population. Analysts view the indication as a meaningful revenue opportunity if approved, given the limited treatment options currently available.
Beyond AXS-05, Axsome’s broader pipeline has also supported sentiment. Quiver Quantitative reported that the company remains on track to submit a New Drug Application for AXS-12, a treatment candidate for narcolepsy with cataplexy, in early 2026. This adds another near-term catalyst and reinforces Axsome’s positioning as a focused neuroscience developer.
Shares of Axsome Therapeutics rallied sharply this week following a major regulatory catalyst, drawing renewed investor attention to the company’s central nervous system pipeline. Axsome stock jumped more than 20% and traded in the low-$180s, marking one of its strongest weekly performances in recent years.
The rally was driven primarily by news that the U.S. Food and Drug Administration granted Priority Review to Axsome’s supplemental New Drug Application for AXS-05 in the treatment of agitation associated with Alzheimer’s disease. As reported by GlobeNewswire, the FDA set a target action date of April 30, 2026, significantly accelerating the regulatory timeline and increasing confidence in a potential label expansion for the company’s lead product.
Market reaction to the FDA decision was swift. Investing*com noted that the Priority Review designation pushed Axsome shares to record levels, reflecting investor optimism around the commercial potential of AXS-05 in a large and underserved patient population. Analysts view the indication as a meaningful revenue opportunity if approved, given the limited treatment options currently available.
Beyond AXS-05, Axsome’s broader pipeline has also supported sentiment. Quiver Quantitative reported that the company remains on track to submit a New Drug Application for AXS-12, a treatment candidate for narcolepsy with cataplexy, in early 2026. This adds another near-term catalyst and reinforces Axsome’s positioning as a focused neuroscience developer.
